rosiglitazone has been researched along with oxazoles in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (48.15) | 29.6817 |
| 2010's | 12 (44.44) | 24.3611 |
| 2020's | 2 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, KK; Glass, CK; Li, AC; Palinski, W; Silvestre, MJ; Willson, TM | 1 |
| Chatterjee, VK; Nugent, C; O'Rahilly, S; Prins, JB; Savage, D; Wentworth, JM; Whitehead, JP | 1 |
| Baker, SF; Brown, J; Davis, B; Hong, G; Khatoon, N | 1 |
| Agostini, M; Chatterjee, VK; Garnes, KT; Gurnell, M; Levinson, SH; O'Rahilly, S; Rajanayagam, O; Savage, DB; Schwabe, JW; Smith, AG; Willson, TM; Wood, EM; Xu, HE | 1 |
| Imoto, H; Kimura, H; Momose, Y; Moriyama, S; Odaka, H; Sakamoto, J; Sawada, H | 1 |
| Chen, J; Chen, Q; Jiang, H; Shen, J; Shen, X; Sun, T | 1 |
| Kaya, T; Sheu, SH; Vajda, S; Waxman, DJ | 1 |
| Biller, S; Cap, M; Chen, S; Cheng, PT; Chu, C; Devasthale, P; Farrelly, D; Fenderson, W; Gregg, R; Gu, L; Hariharan, N; Harrity, T; Jeon, Y; Kunselman, L; Mookhtiar, KA; Ponticiello, R; Qu, F; Ren, J; Ryono, D; Seethala, R; Shao, C; Tieman, A; Wang, W; Wetterau, J; Yang, WP; Zhang, H; Zhou, M | 1 |
| Bansal, VS; Bora, RS; Gupta, A; Khanna, V; Khattar, SK; Mittra, S; Priyadarsiny, P; Roy, S; Saini, KS; Sangle, G; Sattigeri, J; Sharma, L; Sharma, S; Tandon, R | 1 |
| Feng, Y; Hörling, J; Hu, X; Leng, Y; Liu, X; Sydow-Bäckman, M; Yang, YS; Yu, JH; Zhao, XF; Zierath, JR | 1 |
| Kim, JK; Kim, MK; Kim, NJ; Koo, BW; Lee, KO; Li, F; Lim, JI; Min, KH; Park, HJ; Suh, YG; Yoo, JK | 1 |
| Blasi, ER; Ecelbarger, CM; Heyen, JR; McHarg, AD; Tiwari, S | 1 |
| Baader, M; Breitschopf, K; Falk, E; Gerl, M; Kramer, W; Linz, W; Rütten, H; Schäfer, HL; Wohlfart, P | 1 |
| Basu, S; Giri, S; Gite, A; Godha, A; Goswami, A; Jain, M; Patel, P; Pingali, H; Raval, P; Raval, S; Shah, M; Suthar, D | 1 |
| Claude, N; Guillouzo, A; Renaud, MP; Rogue, A; Spire, C | 1 |
| Akiyama, TE; Berger, JP; Castriota, G; Chang, CH; Chen, Y; Doebber, TW; Einstein, M; Lau, F; Li, Y; Liu, K; Liu, W; McCann, ME; McKeever, B; McNamara, L; Meinke, PT; Mosley, RT; Wang, C; Wood, HB; Wu, M; Zhou, G | 1 |
| Falk, E; Glien, M; Glombik, H; Herling, AW; Korn, M; Linz, W; Rütten, H; Schäfer, HL; Wendler, W | 1 |
| Wilding, JP | 1 |
| Amacher, DE; Boucher, GG; Francone, O; Kerlin, RL; Morton, D; Pettersen, JC; Pruimboom-Brees, IM; Will, Y | 1 |
| Das, N; Kumar, P; Moorthy, NS; Shrivastava, SK; Shukla, S; Srivastava, RS; Trivedi, P | 1 |
| Fukui, M; Hinoi, E; Ito, Y; Kitao, T; Kubo, M; Shirahase, H; Yoneda, Y | 1 |
| Brito, JP; Gionfriddo, MR; Leppin, AL; Montori, VM; Morey-Vargas, OL; Murad, MH | 1 |
| Agarwal, AK; Garg, A; Sankella, S | 1 |
| Amoroso, R; Maccallini, C; Mollica, A | 1 |
| Al Sharif, M; Alov, P; Diukendjieva, A; Pajeva, I; Tsakovska, I; Vitcheva, V | 1 |
| Califf, RM; Demets, D; George, JT; Gerstein, HC; Granger, C; Green, JB; Hobbs, T; Holman, RR; Lawson, FC; Leiter, LA; McGuire, DK; McMurray, J; Pagidipati, NJ; Pfeffer, MA; Reusch, J; Riesmeyer, JS; Roe, MT; Rosenberg, Y; Sharma, A; Temple, R; Wiviott, S | 1 |
| Astakhova, AA; Chistyakov, DV; Goriainov, SV; Sergeeva, MG | 1 |
3 review(s) available for rosiglitazone and oxazoles
| Article | Year |
|---|---|
PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
Topics: Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; Humans; Hypoglycemic Agents; Oxazoles; Peroxisome Proliferator-Activated Receptors; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thiophenes; Treatment Outcome | 2012 |
Systematic reviews to ascertain the safety of diabetes medications.
Topics: Acidosis, Lactic; Blood Glucose; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Female; Fractures, Bone; Glycated Hemoglobin; Glycine; Humans; Hypoglycemic Agents; Male; Meta-Analysis as Topic; Metformin; Oxazoles; Pancreatic Neoplasms; Risk Assessment; Rosiglitazone; Thiazolidinediones; Urinary Bladder Neoplasms | 2014 |
The Positive Regulation of eNOS Signaling by PPAR Agonists in Cardiovascular Diseases.
Topics: Animals; Cardiovascular Diseases; Glycine; Humans; Nitric Oxide Synthase Type III; Oxazoles; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Signal Transduction; Thiazolidinediones | 2017 |
24 other study(ies) available for rosiglitazone and oxazoles
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.
Topics: Animals; Arteriosclerosis; Base Sequence; CD36 Antigens; DNA Primers; Female; Gene Expression; Humans; Insulin Resistance; Ligands; Male; Matrix Metalloproteinase 9; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxazoles; Receptors, Cytoplasmic and Nuclear; Receptors, Immunologic; Receptors, LDL; Receptors, Lipoprotein; Receptors, Scavenger; RNA, Messenger; Rosiglitazone; Scavenger Receptors, Class B; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha; Tyrosine | 2000 |
Potentiation of glucose uptake in 3T3-L1 adipocytes by PPAR gamma agonists is maintained in cells expressing a PPAR gamma dominant-negative mutant: evidence for selectivity in the downstream responses to PPAR gamma activation.
Topics: 3T3 Cells; Adenoviridae; Adipocytes; Animals; Benzophenones; Cell Membrane; Drug Synergism; Gene Expression; Glucose; Glucose Transporter Type 1; Glucose Transporter Type 4; Green Fluorescent Proteins; Hypoglycemic Agents; Insulin; Luminescent Proteins; Mice; Monosaccharide Transport Proteins; Muscle Proteins; Mutation; Oxazoles; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transfection; Tyrosine | 2001 |
PPAR gamma-dependent anti-inflammatory action of rosiglitazone in human monocytes: suppression of TNF alpha secretion is not mediated by PTEN regulation.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chromones; Enzyme Activation; Enzyme Inhibitors; Humans; In Vitro Techniques; Monocytes; Morpholines; Oxazoles; Phosphoinositide-3 Kinase Inhibitors; Phosphoric Monoester Hydrolases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Tumor Necrosis Factor-alpha; Tumor Suppressor Proteins; Tyrosine | 2003 |
Tyrosine agonists reverse the molecular defects associated with dominant-negative mutations in human peroxisome proliferator-activated receptor gamma.
Topics: Amino Acid Sequence; Cell Line; Gene Expression; Genes, Dominant; Humans; Leucine; Ligands; Methionine; Models, Structural; Molecular Sequence Data; Monocytes; Mutation; Oxazoles; Pioglitazone; Proline; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Transcription Factors; Transfection; Tyrosine; Valine | 2004 |
A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes.
Topics: 3T3 Cells; Adipocytes; Animals; Butyrates; Chlorocebus aethiops; COS Cells; DNA-Binding Proteins; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Histone Acetyltransferases; Humans; Hypoglycemic Agents; Japan; Mice; Nuclear Receptor Coactivator 1; Oxazoles; PPAR gamma; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transcription Factor AP-2; Transcription Factors; Transfection | 2004 |
A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist.
Topics: alpha-Galactosidase; Anilides; Cells, Cultured; Chromans; CREB-Binding Protein; Drug Evaluation, Preclinical; Genes, Reporter; Indomethacin; Ligands; Nuclear Proteins; Oxazoles; Pioglitazone; PPAR gamma; Prostaglandin D2; Protein Binding; Rosiglitazone; Thiazolidinediones; Trans-Activators; Troglitazone; Two-Hybrid System Techniques; Tyrosine; Yeasts | 2004 |
Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping.
Topics: Alkanesulfonates; Binding Sites; Cinnamates; Computational Biology; Humans; Ligands; Oxazines; Oxazoles; Phenylpropionates; PPAR gamma; Protein Binding; Protein Conformation; Protein Interaction Mapping; Protein Structure, Tertiary; Rosiglitazone; Solvents; Thiazoles; Thiazolidinediones; Thiazolidines; Tyrosine | 2005 |
Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice.
Topics: Adiponectin; Animals; Blood Glucose; Corticosterone; Diabetes Mellitus, Type 2; Diet; Female; Glycine; Hyperlipidemias; Hypoglycemic Agents; Insulin; Insulin-Secreting Cells; Liver; Mice; Obesity; Oxazoles; Peroxisome Proliferator-Activated Receptors; Rosiglitazone; Thiazolidinediones | 2006 |
Increase in weight induced by muraglitazar, a dual PPARalpha/gamma agonist, in db/db mice: adipogenesis/or oedema?
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Blood Glucose; Body Weight; Cell Differentiation; Edema; Epithelial Sodium Channels; Erythrocyte Count; Fatty Acids; Glycine; Hemoglobins; Kidney; Mice; Mice, Inbred Strains; Oxazoles; PPAR alpha; PPAR gamma; RNA, Messenger; Rosiglitazone; Sodium; Sodium-Potassium-Exchanging ATPase; Thiazolidinediones; Transcriptional Activation | 2007 |
Effect of a novel non-thiazolidinedione peroxisome proliferator-activated receptor alpha/gamma agonist on glucose uptake.
Topics: 3T3 Cells; Adenocarcinoma; Animals; Biological Transport; Cell Line, Tumor; Colonic Neoplasms; Coumarins; Genes, Reporter; Glucose; Humans; Mice; Muscle, Skeletal; Oxazoles; PPAR alpha; PPAR gamma; Rosiglitazone; Thiazolidinediones | 2007 |
Design, synthesis, and structure-activity relationship of carbamate-tethered aryl propanoic acids as novel PPARalpha/gamma dual agonists.
Topics: Carbamates; Chemistry, Pharmaceutical; Drug Design; Glycine; Models, Chemical; Models, Molecular; Molecular Structure; Oxazoles; PPAR alpha; PPAR gamma; Propionates; Rosiglitazone; Stereoisomerism; Structure-Activity Relationship; Thiazolidinediones; Transcriptional Activation | 2007 |
Time course of AQP-2 and ENaC regulation in the kidney in response to PPAR agonists associated with marked edema in rats.
Topics: Adiponectin; Animals; Aquaporin 2; Blood Pressure; Edema; Epithelial Sodium Channels; Insulin; Kidney; Male; Natriuresis; Oxazoles; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones; Triazoles; Water-Electrolyte Balance | 2008 |
The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzoates; Biomarkers; Cardiotonic Agents; Cell Line; Disease Progression; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Male; Molecular Structure; Nitric Oxide Synthase Type III; Oxazoles; PPAR alpha; Ramipril; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Rosiglitazone; Survival Rate; Thiazolidinediones | 2009 |
Revisiting glitazars: thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents.
Topics: Administration, Oral; Animals; Cell Line; Dose-Response Relationship, Drug; Hypoglycemic Agents; Inhibitory Concentration 50; Mice; Molecular Structure; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Protein Binding; Rats; Rats, Wistar; Rosiglitazone; Thiazolidinediones; Thiophenes | 2011 |
Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in rat hepatocytes.
Topics: Alkanesulfonates; Animals; Chromans; Gene Expression Profiling; Genes; Glycine; Hepatocytes; Humans; Male; Oligonucleotide Array Sequence Analysis; Oxazoles; Phenylpropionates; PPAR alpha; PPAR gamma; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Troglitazone | 2011 |
Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor γ (PPARγ) modulators.
Topics: Animals; Benzimidazoles; Binding Sites; Chlorocebus aethiops; COS Cells; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dimethadione; Drug Partial Agonism; Gene Expression Profiling; Humans; Hypoglycemic Agents; Male; Mice; Models, Molecular; Mutagenesis; Nuclear Receptor Coactivators; Oxazoles; Pioglitazone; PPAR gamma; Protein Conformation; Rats; Rats, Zucker; Rosiglitazone; Structure-Activity Relationship; Thiazolidinediones; Transcriptional Activation | 2011 |
AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats.
Topics: Animals; Benzoates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Glucose; Humans; Hypoglycemic Agents; Lipid Metabolism; Lipids; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Oxazoles; PPAR alpha; Rats; Rats, Zucker; Rosiglitazone; Thiazolidinediones | 2012 |
The development of subcutaneous sarcomas in rodents exposed to peroxisome proliferators agonists: hypothetical mechanisms of action and de-risking attitude.
Topics: Adipogenesis; Adipose Tissue, Brown; Adipose Tissue, White; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; DNA Damage; Glycine; Hypoglycemic Agents; Ion Channels; Mice; Mitochondria; Mitochondrial Proteins; Oxazoles; Oxidative Stress; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Pioglitazone; PPAR alpha; PPAR gamma; Rats; RNA-Binding Proteins; Rodentia; Rosiglitazone; Sarcoma; Thermogenesis; Thiazolidinediones; Transcription Factors; Troglitazone; Uncoupling Protein 1 | 2012 |
Synthesis, characterization, biological evaluation and docking of coumarin coupled thiazolidinedione derivatives and its bioisosteres as PPARγ agonists.
Topics: Animals; Benzaldehydes; Computer Simulation; Coumarins; Diabetes Mellitus, Experimental; Esters; Hydantoins; Hypoglycemic Agents; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Models, Molecular; Oxazoles; PPAR gamma; Rats; Rats, Wistar; Rosiglitazone; Spectroscopy, Fourier Transform Infrared; Stereoisomerism; Streptozocin; Thiazolidinediones | 2012 |
Insulin sensitization by a novel partial peroxisome proliferator-activated receptor γ agonist with protein tyrosine phosphatase 1B inhibitory activity in experimental osteoporotic rats.
Topics: Adipocytes; Animals; Bone Density; Cell Differentiation; Cells, Cultured; Diabetes Mellitus, Type 2; Disease Models, Animal; Fatty Acids, Nonesterified; Female; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Isoquinolines; Osteoblasts; Osteoporosis, Postmenopausal; Ovariectomy; Oxazoles; PPAR gamma; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Rats; Rats, Inbred F344; Receptor, Insulin; Risk; Rosiglitazone; Thiazolidinediones; Triglycerides | 2014 |
Characterization of the Mouse and Human Monoacylglycerol O-Acyltransferase 1 (Mogat1) Promoter in Human Kidney Proximal Tubule and Rat Liver Cells.
Topics: Acyltransferases; Anilides; Animals; Blotting, Northern; Caco-2 Cells; Cell Line; Cell Line, Tumor; Chromatin Immunoprecipitation; Computational Biology; HT29 Cells; Humans; Kidney Tubules, Proximal; Liver; Mice; Oxazoles; PPAR alpha; Promoter Regions, Genetic; Pyrimidines; Rats; Real-Time Polymerase Chain Reaction; Rosiglitazone; Sulfones; Thiazoles; Thiazolidinediones; Thiophenes; Tyrosine | 2016 |
Molecular Modeling Approach to Study the PPARγ-Ligand Interactions.
Topics: Humans; Hypoglycemic Agents; Ligands; Molecular Docking Simulation; Oxazoles; PPAR gamma; Protein Conformation; Quantitative Structure-Activity Relationship; Rosiglitazone; Tyrosine | 2019 |
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions; Glucose; Glycated Hemoglobin; Glycine; Government Regulation; Humans; Hypoglycemic Agents; Oxazoles; Phenylbutazone; Practice Guidelines as Topic; Risk; Rosiglitazone; Tolbutamide; United States; United States Food and Drug Administration | 2020 |
Comparison of PPAR Ligands as Modulators of Resolution of Inflammation, via Their Influence on Cytokines and Oxylipins Release in Astrocytes.
Topics: Anilides; Animals; Anti-Inflammatory Agents; Astrocytes; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Fenofibrate; Interleukin-10; Lipopolysaccharides; MAP Kinase Kinase 4; Oxazoles; Oxylipins; p38 Mitogen-Activated Protein Kinases; PPAR gamma; PPAR-beta; Rats; Rats, Wistar; Rosiglitazone; Thiazoles; Tumor Necrosis Factor-alpha; Tyrosine | 2020 |